When Do GLP-1 Patents Expire? The Complete Generic Timeline

GLP-1 receptor agonists have transformed the treatment of obesity and type 2 diabetes, but access remains severely limited by cost. Semaglutide (Ozempic, Wegovy) costs over $1,000/month in the US without insurance. Tirzepatide (Mounjaro, Zepbound) is similarly priced. For millions of patients, the practical question isn't which GLP-1 is best — it's when will I be able to afford one? The answer depends on patent expiration dates, and those dates vary dramatically by drug, by country, and by how aggressively manufacturers defend their patent portfolios. Novo Nordisk has filed 320 US patent applications for semaglutide alone, with 154 granted and follow-on patents extending potential protection to 2042 — 16 years beyond the original compound patent. Understanding this landscape is essential for anyone planning long-term GLP-1 therapy.

Not all GLP-1 drugs are created equal. The weight loss efficacy gap between the cheapest (generic) options and the patent-protected ones is substantial — which is exactly why patent timelines matter so much. Here's what the clinical trials show for mean percent body weight loss at standard doses: Liraglutide (Saxenda): ~5.8% placebo-adjusted weight loss. The first-generation option, now generic. Modest but meaningful. Semaglutide 2.4 mg injection (Wegovy): ~13.9% weight loss. The current standard-bearer, with the broadest clinical evidence base. Oral semaglutide 50 mg (Rybelsus): ~12.7% weight loss. Slightly less effective than injectable, but no needles. Tirzepatide 15 mg (Zepbound): ~17.8% weight loss. The dual GIP/GLP-1 agonist outperforms semaglutide, but won't go generic until 2036. CagriSema (Phase 3, not yet approved): ~22.7% weight loss in the REDEFINE 1 trial. Combines semaglutide with cagrilintide. 60% of participants lost at least 20%, and 23% lost 30% or more. FDA decision expected late 2026. Retatrutide (Phase 3, not yet approved): ~24.2% weight loss at 12 mg. The triple GIP/GLP-1/glucagon agonist produced the highest weight loss of any GLP-1 class drug tested to date. The pattern is clear: the most effective drugs are also the ones with the longest patent protection. Generic liraglutide delivers roughly one-third the weight loss of tirzepatide or retatrutide. For patients choosing between an affordable generic and a patent-protected blockbuster, the efficacy difference is not trivial.

Liraglutide (Victoza for diabetes, Saxenda for weight loss) became the first GLP-1 receptor agonist to go generic. The FDA approved Teva's generic liraglutide injection in August 2025, followed by Biocon's approval in February 2026. The initial price savings are modest: generic liraglutide launched at approximately $1,165/month versus brand Saxenda at $1,300-1,800/month — a savings of roughly $135-200/month at the wholesale level. But as additional manufacturers enter the market through 2026, prices are expected to drop significantly, potentially by up to 70% in price-sensitive markets. Liraglutide is a first-generation GLP-1 agonist with more modest weight loss than newer agents. But at a fraction of the price, it may become the default entry point for patients who can't access or afford semaglutide or tirzepatide.

Semaglutide is where things get complicated — and where the most money is at stake. The original compound patent (US Patent No. 8,536,122) has a nominal expiration of March 20, 2026. But a second patent (US Patent No. 8,129,343) was extended by over five years through Patent Term Adjustment and Patent Term Extension, pushing US protection to December 5, 2031. Beyond that, 49 follow-on patents cover formulations, devices, and methods of treatment, with the latest extending to 2042. **Outside the US, it's a different story.** Canada became the first G7 nation where semaglutide patents expired on January 4, 2026, triggering immediate generic filings from Sandoz, Apotex, Teva, and Aspen. India and China patent expirations hit in March 2026, with at least 17 generic semaglutide candidates already in Phase 3 trials in China and 50+ brands preparing to launch in India. Brazil follows the same March 2026 timeline. The projected revenue Novo Nordisk will earn during the US patent extension period (2026-2031) alone is estimated at $166 billion — which explains why they've filed over 300 patent applications to protect this franchise. **Oral semaglutide (Rybelsus)** has additional layers of protection. The proprietary SNAC absorption-enhancing technology has its own patent portfolio, with one key patent extending to 2039. Generic manufacturers would need to either develop alternative oral delivery technology or wait for these patents to expire, pushing generic oral semaglutide availability to the early-to-mid 2030s.

Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) has the most distant generic timeline among currently approved GLP-1 drugs. The main compound patent (US Patent No. 9,474,780) doesn't expire until January 2036. Follow-on patents extend potential protection to 2041. Eli Lilly has filed 53 US patent applications with 16 granted so far. Patent challenges become eligible on May 13, 2026 (potentially extended six months if pediatric exclusivity is granted), but even successful challenges would take years to litigate. Realistic expectations for generic tirzepatide: 2036 at the earliest, possibly 2041. Lilly is investing accordingly — $7.8 billion in manufacturing expansion during 2025 alone, betting that tirzepatide will remain a cash-generating blockbuster for at least another decade.

**Exenatide (Byetta):** Already has a generic version available in the US. As the oldest GLP-1 agonist (twice-daily injection), it's rarely prescribed for new patients but remains the most affordable option. **Dulaglutide (Trulicity):** Generic entry projected for late 2027. As a weekly injection with moderate efficacy, generic dulaglutide could become a solid mid-tier option for cost-conscious patients. **Retatrutide (Eli Lilly, Phase 3):** Not yet approved, but Lilly is seeking biologic designation rather than small-molecule status. If granted, this would provide 12 years of market exclusivity instead of 5 — potentially blocking generics until the late 2030s even without extensive patent filings. **CagriSema (Novo Nordisk, Phase 3):** Combines semaglutide with cagrilintide, a novel amylin analog. The semaglutide component faces existing patent timelines, but cagrilintide would carry its own patent protection, effectively extending the franchise.

The GLP-1 market exemplifies a broader pharmaceutical strategy known as "patent thicketing" — filing large numbers of follow-on patents for minor modifications to extend market exclusivity well beyond the original compound patent. To understand why this matters, it helps to know how drug patents work. The original "compound patent" covers the molecule itself — semaglutide, the chemical entity. This is the foundational patent, and for semaglutide it would have expired in March 2026. But manufacturers can file additional "follow-on" patents that cover everything around the molecule: specific formulations (how it's mixed and stabilized), delivery devices (the pen injector design), dosing regimens (the specific titration schedule), methods of treatment (using semaglutide for obesity vs. diabetes vs. cardiovascular risk), and manufacturing processes. Each of these can carry its own 20-year patent term. A generic manufacturer must either design around every active follow-on patent or wait for them all to expire — even if the molecule itself is off-patent. Novo Nordisk's semaglutide portfolio illustrates the scale: 320 patent applications, 154 granted. The breakdown: 91 formulation patents, 41 delivery device patents, and 45 method-of-treatment patents. The original compound protection would have expired in 2026; the thicket extends potential protection to 2042 — 16 additional years of exclusivity built on patents that cover not the molecule, but everything surrounding it. For patients, this means the price relief that patent expiration normally brings may be delayed by a decade or more — even when the fundamental molecule is no longer novel. Advocacy organizations like I-MAK have documented this pattern across the GLP-1 class, arguing it represents a form of patent abuse that keeps prices artificially high.

The practical picture right now: **Available or imminent generics:** Liraglutide (available now, prices declining), exenatide (available now). **Available outside the US:** Generic semaglutide is launching in Canada, India, China, and Brazil in 2026, though these products won't be legally importable to the US. **Years away in the US:** Generic semaglutide (2031-2032 at earliest), generic tirzepatide (2036 at earliest), generic oral semaglutide (mid-2030s). **Compounding as a bridge:** Some patients currently access compounded semaglutide and tirzepatide through 503B compounding pharmacies, though this avenue faces ongoing legal and regulatory challenges following the FDA's efforts to restrict compounding of GLP-1 drugs. The bottom line: if you need an affordable GLP-1 today, generic liraglutide is your best option. If you're waiting for affordable semaglutide or tirzepatide in the US, plan for a wait of 5-10+ years — unless patent challenges, legislative action, or compounding access change the equation.